Genevant Sciences Corporation is a leading nucleic acid delivery company with a focus on developing innovative medicines. With a strong emphasis on technology, they possess world-class platforms and an extensive lipid nanoparticle (LNP) patent estate. Genevant has decades of experience and expertise in nucleic acid drug delivery and development, making them a trusted choice in the industry.

Their proprietary platforms allow them to work with diverse constructs, enabling rapid advancement of products from the lab to the clinic. Genevant collaborates selectively with leading pharmaceutical and biotechnology companies, providing access to their platforms, technologies, systems, and patent estate. With over 500 novel, in-house lipid compounds and a track record of success, Genevant has evaluated their LNP technology across more than a dozen clinical programs involving 600+ subjects.

They hold over 700 patents worldwide and have achieved the first siRNA-LNP product to receive regulatory approval. Their LNP technology has also demonstrated successful gene silencing in nonhuman primates as published in Nature. Genevant's commitment to overcoming the challenges of nucleic acid delivery presents endless possibilities for the future of human health.

They are dedicated to pushing boundaries and transforming the lives of patients. Connect with them to explore the pioneering work they do